Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report
DOI:
https://doi.org/10.2340/actadv.v102.1378Abstract
Abstract is missing (Short communication)
Downloads
References
Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, et al. Paraneoplastic pemphigus: insight into the autoimmune pathogenesis, clinical features and therapy. Int J Mol Sci 2017; 18: 2532.
https://doi.org/10.3390/ijms18122532 DOI: https://doi.org/10.3390/ijms18122532
Wang M, Li F, Wang X, Wang X, Wang R, Yang Y, et al. Features and risk factors for paraneoplastic autoimmune multiorgan syndrome in 145 Chinese patients. Acta Derm Venereol 2020; 100: adv00312.
https://doi.org/10.2340/00015555-3673 DOI: https://doi.org/10.2340/00015555-3673
Ouedraogo E, Gottlieb J, de Masson A, Lepelletier C, Jachiet M, Salle de Chou C, et al. Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults. J Am Acad Dermatol 2019; 80: 1544-1549.
https://doi.org/10.1016/j.jaad.2018.03.043 DOI: https://doi.org/10.1016/j.jaad.2018.03.043
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29: 2062-2068.
https://doi.org/10.1038/leu.2015.212 DOI: https://doi.org/10.1038/leu.2015.212
Takahashi H, Kouno M, Nagao K, Wada N, Hata T, Nishimoto S, et al. Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice. J Clin Invest 2011; 121: 3677-3688.
https://doi.org/10.1172/JCI57379 DOI: https://doi.org/10.1172/JCI57379
McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet 2021; 398: 803-816.
https://doi.org/10.1016/S0140-6736(21)00438-4 DOI: https://doi.org/10.1016/S0140-6736(21)00438-4
Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014; 123: 3832-3842.
https://doi.org/10.1182/blood-2013-12-543736 DOI: https://doi.org/10.1182/blood-2013-12-543736
Sarny S, Hucke M, El-Shabrawi Y. Treatment of mucous membrane pemphigoid with janus kinase inhibitor baricitinib. JAMA Ophthalmol 2018; 136: 1420-1422.
https://doi.org/10.1001/jamaophthalmol.2018.3789 DOI: https://doi.org/10.1001/jamaophthalmol.2018.3789
James H, Paley GL, Brasington R, Custer PL, Margolis TP, Paley MA. Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep 2021; 22: 101104.
https://doi.org/10.1016/j.ajoc.2021.101104 DOI: https://doi.org/10.1016/j.ajoc.2021.101104
Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J Med 2014; 370: 1820-1828.
https://doi.org/10.1056/NEJMra1204664 DOI: https://doi.org/10.1056/NEJMra1204664
Zhao Y, OuYang G, Shi J, Luo Y, Tan Y, Yu J, et al. Salvage therapy with low-dose ruxolitinib leads to a significant improvement in bronchiolitis obliterans syndrome in patients with cGVHD after allogeneic hematopoietic stem cell transplantation. Front Pharmacol 2021; 12: 668825.
https://doi.org/10.3389/fphar.2021.668825 DOI: https://doi.org/10.3389/fphar.2021.668825
Kaurinovic M, Delli K, Jonk AE, Biswana A, Hazenberg CLE, Choi G, et al. Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic graft-versus-host disease and oral involvement. Clin Oral Investig 2022; 26: 4209-4216.
https://doi.org/10.1007/s00784-022-04393-1 DOI: https://doi.org/10.1007/s00784-022-04393-1
Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.
https://doi.org/10.1016/S0140-6736(09)60237-3 DOI: https://doi.org/10.1016/S0140-6736(09)60237-3
Wang D, Liu Y, Lai X, Chen J, Cheng Q, Ma X, et al. Efficiency and toxicity of ruxolitinib as a salvage treatment for steroid-refractory chronic graft-versus-host disease. Front Immunol 2021; 12: 673636.
https://doi.org/10.3389/fimmu.2021.673636 DOI: https://doi.org/10.3389/fimmu.2021.673636
Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol 2018; 93: 339-347.
https://doi.org/10.1002/ajh.24976 DOI: https://doi.org/10.1002/ajh.24976
Published
How to Cite
License
Copyright (c) 2022 Birao Fan, Mingyue Wang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
